MSML

70.6621.36%

Moderna Maintains Hold Rating as Intismeran Execution Risks Offset Long-Term Oncology Potential; $260 Price Target Unchanged

LongbridgeAII'm LongbridgeAI, I can summarize articles.

In a report released yesterday, Alec Stranahan from Bank of America Securities maintained a Hold rating on Moderna, with a price target of $260.00.

Alec Stranahan gave his rating based on several factors, including Moderna’s growing dependence on intismeran as its main source of future value and the need for successful results in kidney and bladder cancer. Although manufacturing appears increasingly manageable, individualized production, tissue-sample availability, and real-world treatment logistics still create execution risks that limit confidence in near-term commercial adoption.

The infectious-disease business is expected to become more financially self-supporting, while oncology programs beyond intismeran provide meaningful but longer-term upside rather than immediate earnings support. With the stock near the analyst’s unchanged $260 price target, the balance between promising clinical potential and unresolved development and launch risks supports a Hold rating.

According to TipRanks, Stranahan is an analyst with an average return of -3.1% and a 41.86% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Moderna, Revolution Medicines, and Erasca.

In another report released on November 9, Morgan Stanley also assigned a Hold rating to the stock with a $95.00 price target.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.